1. Home
  2. Analysis
  3. Lantus
  4. Micronor

Lantus and Micronor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lantus and Micronor. Common interactions include drug ineffective among females.

The phase IV clinical study analyzes what interactions people who take Lantus and Micronor have. It is created by eHealthMe based on reports of 11 people who take Lantus and Micronor from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 30, 2022

11 people who take Lantus and Micronor together, and have interactions are studied.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 176,435 Lantus users for its effectiveness, alternative drugs and more.

What is Micronor?

Micronor has active ingredients of norethindrone. It is often used in birth control. eHealthMe is studying from 1,265 Micronor users for its effectiveness, alternative drugs and more.

Number of Lantus and Micronor reports submitted per year:

Lantus and Micronor drug interactions.

Common Lantus and Micronor drug interactions by gender *:

female:

  1. Drug ineffective
  2. Localised infection
  3. Disorientation
  4. Nausea
  5. Vision blurred
  6. Arthropathy
  7. Back disorder
  8. Asthma
  9. Pain
  10. Diabetic ketoacidosis

male:

n/a

Common Lantus and Micronor drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Pain
  2. Diabetic ketoacidosis
  3. Renal injury
  4. Drug ineffective
  5. Localised infection
  6. Arthropathy
  7. Back disorder
  8. Asthma

50-59:

  1. Arthralgia
  2. Asthenia
  3. Disorientation
  4. Nausea
  5. Vision blurred

60+:

n/a

Common conditions people have *:

  1. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 7 people, 63.64%
  2. Pain: 7 people, 63.64%
  3. Neuropathy Peripheral (surface nerve damage): 7 people, 63.64%
  4. Muscle Spasms (muscle contraction): 7 people, 63.64%
  5. Type 2 Diabetes: 2 people, 18.18%
  6. Stress And Anxiety: 2 people, 18.18%
  7. Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 9.09%
  8. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and Micronor?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Lantus and Micronor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Lantus side effects:

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Lantus interactions:

Browse all interactions between Lantus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant and norethindrone (the active ingredients of Lantus and Micronor, respectively), and Lantus and Micronor (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Lantus and Micronor.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.